Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
Genitrix has extended its Dentagen dental care range with the addition of Dentagen Aqua, a water additive treatment to control plaque and prevent bad breath in cats and dogs.
Genitrix says the product offers a completely new approach to dental care for companion animals and is expected to prove particularly effective in treating cats which do not respond well to existing treatments, such as dental chews and tooth-brushing.
Dentagen Aqua is a palatable liquid which is added to a pet's drinking water on a daily basis. Its active principal is RF2, a plant extract. According to the company, RF2's ability to enable natural and healthy mouth bacteria to flourish while inhibiting the formation of plaque even at low concentrations has been demonstrated in extensive clinical trials. It operates as an 'anti-biofilm' treatment, modifying the growth of the membrane of oral bacteria to prevent them from producing plaque.
Dentagen Aqua is supplied in a 250 ml bottle costing £6.80. At the recommended dose of 5 ml per day, the bottle will provide 50 days' treatment for a cat or small dog.
In 2008, Genitrix launched the original Dentagen plaque protection system which consists of a unique RF2-impregnated wax provided to practices in a syringe to be applied to the gingival layer and the buccal area of teeth of dogs or cats at end of dental procedures. Dog owners can then maintain the protective coating by giving their pet Dentagen plaque prevention chews. The launch of Dentagen Aqua means that an equivalent solution is now available for cat owners or for dogs which don't eat chews.
With over 85% of dogs and cats over three years old suffering from some form of dental or gum disease, it's the most common health problem in these animals. The market for preventative dental healthcare supplements is estimated to be close to £1 million per annum.
Rob Watkins, Marketing Director at Genitrix, said: "Dentagen exceeded our expectations during its first year and has proved popular with both vets and dog owners. Given the vital importance of good dental health for dogs and cats, it seemed the logical next step to produce a water additive version to make the treatment easier for cat owners in particular."
Henry, who works at Crowshall Veterinary Services in Norfolk, graduated from the Royal Veterinary College in 2018.
He is the lead products export vet for Crowshall and was instrumental in the business’s preparation for Brexit.
He is also one of the founding ‘green champions’ at the practice, which has become the first specialist poultry practice to be accredited with Investors in the Environment.
The panel of seven judges from said that within just three years Henry has gained much experience, showing evidence that he has contributed to reduced antibiotic usage as well as improved biosecurity and improved bird welfare, health and production for his clients.
They said: “He has clearly shown he has worked with colleagues as a team, and has introduced new initiatives in his practice including improving mental health of staff and assisting in sustainability.”
James Porritt, National Pig and Poultry Sales Manager of award sponsors Zoetis, said all three finalists were very strong candidates: “It was great to see the work they have all done recognised at the awards.
"It was fantastic to see Henry win and hope the award spurs him on to continue his bright future in the poultry industry.”
Photo: Henry Lamb holding the Young Farm Vet trophy, alongside Jonathan Agnew (left) and James Porritt of the award sponsors Zoetis
ECM of France, a specialist in veterinary ultrasound solutions, has launched VIRTUAL SCAN - an ultrasound scanner for pig farmers and veterinarians. ECM says the scanner offers an alternative to screenless A-Mode Doppler devices, cheaper ultrasound devices, which are often poor quality.
VIRTUAL SCAN weighs 450 grams. It is equipped with an internal five-hour battery and a 5MHz sector probe. ECM says the instrument is extremely easy to handle - all the user needs to do is switch it on and the hand-held instrument is instantly ready to perform an ultrasound on sows.
VIRTUAL SCAN is a compact device (11cm x 18.5cm x 4.5cm) and does not require an external cable. According to the company, it can be used in any livestock facility, even inside narrow, hard-to-reach stalls. The screen is positioned in such a way that the image is always visible.
Using ECM's scanner, pregnancy tests can be performed as early as 21 days after insemination, so it is possible to re-inseminate any unfertilised sow without wasting a costly additional cycle. The image is easy to interpret. After use, the VIRTUAL SCAN ultrasound instrument is easy to clean with a damp cloth or water.
ECM, which is headquartered in Angoulême (in south-western France), develops and manufactures specialist veterinary-science devices. The company also provides training in ultrasound techniques, the correct way to move the probe and how to interpret the ultrasound image.
For more information, please contact:
Simon QuarmbyHOLMEFIELD Farm ServiceAgriculture HouseMurton LaneMurtonYorkT019 5UF
tel : (44) 1904 481.490fax : (44) 1904 481.211email : simon@hfsvets.com
Or visit: http://www.agroscan.com/ and http://www.ecmscan.com/
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).
Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report1 which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.
To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).
The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels. Both advertisements are 30 seconds long.
Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.
Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."
For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.
Ms Bucur MRCVS faced three charges against her.
The first charge was that in April 2024, she wrote a prescription for 60 tablets of tramadol 50mg, indicating that it was for the treatment of an animal, when it was intended for the treatment of a human.
The second charge was that she allowed the prescription to be presented at a pharmacy and/or failed to stop that.
The third charge was that her conduct, in relation to the first two charges was dishonest, and misleading, and took place in circumstances where she was not professionally qualified to write a prescription for human use.
At the outset of the hearing, Ms Bucur admitted all the charges and the Committee accepted her admissions.
In relation to charge three, the Committee found that Ms Bucur had been aware that she should not have written the prescription, that she should not have indicated that it was for an animal, that she should not have deleted the prescription for the clinical record on the practice management system, and she should not have allowed or failed to prevent the prescription from being presented for dispensing.
The Committee therefore found all charges proved.
In terms of aggravating factors, the Committee considered that Ms Bucur’s conduct had given rise to a risk of injury because she was not professionally qualified or sufficiently informed to issue a prescription for tramadol, that she had acted recklessly with regard to the potential effects of a controlled, potentially addictive drug and that her conduct had been premeditated.
It also accepted the submission that there was an abuse of Ms Bucur’s professional position as a registered veterinary surgeon, because this had allowed her to issue a prescription.
The Committee also found that Ms Bucur’s conduct was aggravated by her having involved other persons in her misconduct, namely her partner, in an attempt to have the prescription dispensed.
The Committee noted that the charges involved findings of dishonesty, which is regarded at the higher end in terms of the spectrum of gravity of misconduct.
In mitigation, the Committee took into account that the facts proved related to a single incident of the issuing and attempted use of a prescription.
The Committee was of the view that the Ms Bucur’s conduct had failed to promote protection of public health and had breached the legislation around access to controlled drugs.
Even though this was a single incident, the Committee considered that members of the public, if aware of the facts, would be alarmed and concerned at Ms Bucur’s actions.
As a result, the profession could be brought into disrepute and public confidence in the profession undermined.
The Committee therefore found that Ms Bucur’s conduct amounted to serious professional misconduct in a professional respect.
The Committee then considered whether there were any relevant additional personal aggravating or mitigating factors.
The Committee did not find any further aggravating factors; in mitigation it noted that Ms Bucur had no previous complaints of adverse matters in her career.
The Committee accepted that Ms Bucur had made early, open and frank admissions to her conduct.
She had also offered a fulsome and genuine apology and remorse in her witness statement and in the hearing.
The Committee also accepted that she had since worked without further incident and concluded from her witness statement and evidence that she had developed full insight into her misconduct.
She was able to provide a notable number of references and testimonials which were uniform in speaking to her positive qualities as a veterinary surgeon.
The Committee was able to conclude that this has been a very serious but single lapse of judgement, and that there was a relevant context in that Ms Bucur had clearly acted out of concerns to help her father, however misguided.
There were no suggestions of harm, or risk of harm, to animals.
However, the Committee could not ignore that Ms Bucur’s misconduct had occurred in relation to a controlled drug and had contravened important protections designed to protect the public.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee balanced the effect that a suspension would have on Dr Bucur, by depriving her of the ability to practise for a period, with the public interest.
"However, it decided that, in the circumstances, the interests of protecting the public, including the wider public interest, outweighed Dr Bucur’s interests.
“The Committee decided that, in all the circumstances, a suspension was the appropriate and proportionate sanction.
“The Committee considered for how long the suspension should be imposed.
"It considered that the suspension was not required to allow for Dr Bucur to gain any further insight.
"It would purely be required to mark the Committee’s disapproval of Dr Bucur’s misconduct, as a signal to the public and to the profession.
"The Committee concluded that the least period required in all the circumstances is two months.
“The Committee therefore directed to the Registrar that Dr Bucur’s registration be suspended for a period of two months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
The British Equine Veterinary Association has published the results of a survey it commissioned which found that horse vets in the UK are probably at greater risk of injury than any other civilian profession, including the prison service.
For the study, which was conducted by the Institute of Health and Wellbeing and the School of Veterinary Medicine at the University of Glasgow, 620 equine vets completed a work-related injuries questionnaire. The results of the study indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
If the 620 respondents were representative of the rest of the profession, the injuries they reported would equate to 26,452 per 100,000 equine vets in employment per year. That compares with 10,760 for people working in the prison service, 8,700 for policemen below the rank of sergeant, 6,980 for welders, metal formers and related trades, and 4,760 for construction workers.
Participants were asked to describe their worst-ever injury. Most were described as bruising, fracture and laceration, with the most common site of injury being the leg (29%), followed by the head (23%). The main cause of injury was a kick with a hind limb (49%), followed by strike with a fore limb (11%), followed by crush injury (5%). Nearly a quarter of these reported injuries required hospital admission and notably, 7% resulted in loss of consciousness. The most common reason for the examination during which the injury occurred was foot lameness, followed by dental and female reproductive.
BEVA Past-President Keith Chandler said: “We were shocked to discover the extent of the injuries sustained. Of greatest concern is the number of vets who suffered head injuries and unconsciousness. These injuries appeared to be more common when certain procedures were being performed, such as endoscopy of the upper respiratory tract, when vets are often only partly sighted while using examination equipment, or during wound management and bandage-changes, where vets are often crouched-down for long periods, next to the patient.”
38% of the ‘worst’ injuries occurred when the vet was working with a ‘pleasure’ horse and most frequently (48% of all responses) the horse handler was the owner or the client at the time of the injury. Whilst the number of laypersons or handlers injured at the same time was low, Tim Parkin, vet and lead researcher, pointed out: “This work should act as a wake up call to all involved in the training, employment and engagement of equine vets. The risks associated with handling and working with horses should be the primary consideration for equine vets and horses owners alike, every time a horse is examined or treated. In addition, the experience of the horse handler should be considered when undertaking riskier procedures.”
David Mountford, Chief Executive of BEVA said: “The results are very concerning and justify a careful prospective scientific quantification of the risks. In the short term, knowledge of these risks allows us to better inform all vets who work with horses. In turn vets will be able to inform horse owners, horse-keepers and trainers of the risks, and this may provide justification for having trained assistance on-hand or the more extensive use of sedative drugs in practice, potentially reducing the risk of injury.
"The British Equine Veterinary Association will now look to work with the Health and Safety Executive, Veterinary Schools, large employers of vets in the UK and our members to help develop policies to mitigate the risk of serious injury for vets working with horses.”
Photograph courtesy Towcester Veterinary Centre
CVS says that in the USA, the veterinary profession is the fifth highest profession for non-fatal injuries, with equine veterinarians sustaining an average of eight serious injuries during their career.
‘The context, consequence and prevention of veterinary workplace injuries: a qualitative and quantitative study in the UK’ will be undertaken at the University of Liverpool in collaboration with CVS colleagues as part of its Clinical Research Awards.
The study will run for three years, supported by £74,400 of CVS funding.
The research will investigate what veterinary injuries are, what context they occur in and what their consequences are.
It will look to highlight areas of the profession where injury prevention training and strategies can be developed and adopted to improve the safety of working in veterinary practice.
For the first phase, University of Liverpool researchers have rolled out the largest ever survey to explore veterinary workplace injuries with over 5,000 CVS staff UK-wide.
The survey investigates how veterinary professionals define injuries, their specific causal mechanisms, and why individuals do or do not report injuries or seek medical treatment.
The survey will be followed by an independent audit of CVS’ accident reporting system.
The results of these two activities will lead to the development of a suite of industry leading ‘open access’ educational tools aimed at promoting injury awareness and prevention to help drive behaviour change and support injury avoidance.\
The research project is being led by Dr. John Tulloch, a Research Fellow and European Specialist in Veterinary Public Health, at the University of Liverpool.
Collaborators include CVS Head of Health and Safety Rebecca Jackson and Director of Learning, Education and Development Dr Martin Whiting.
John said: “Injuries that occur within veterinary practice can tragically at times be life-changing and are often avoidable.
"Currently we do not know some critical details that would help to improve safety within the veterinary workplace.
"If we can better understand these details, we will be able to develop and strengthen prevention measures through policy, education, and training.
"We anticipate that this project will result in safer workplaces within the wider veterinary community and, indirectly, in improved animal treatment through a fitter, healthier and safer profession.”
Willows says it is currently the only centre in the UK to offer the procedure, and one of very few in the world.
Simon Swift, an RCVS and European specialist in small animal cardiology (pictured right), heads the cardiology team at Willows.
He said: “Transcatheter edge-to-edge mitral valve repair (TEER) is already considered an alternative to surgical repair in human patients and there have been some very promising early clinical results in dogs.
“The procedure is performed under general anaesthesia through a small incision in the chest wall.
“Access within the beating heart is achieved by a needle puncture at the apex of the heart which is highlighted by continuous X-ray images and an ultrasound of the heart via a probe placed in the oesophagus.
“This allows correct positioning of a V-clamp across the mitral valve to reduce the amount of leakage.
“It’s a procedure that delivers meaningful results and an improved quality of life and, because it’s a minimally invasive process, patients are typically discharged from hospital within two days.”
www.willows.uk.net
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
The RCVS Disciplinary Committee has directed that the name of a veterinary surgeon who formerly practised in Norwich should be removed from the Register, having found him unfit to practise veterinary surgery following his Crown Court conviction for fraud.
During the one-day hearing, the Disciplinary Committee heard how Francisco da Cruz had abused his position whilst practising as a veterinary surgeon at Hellesdon Vets, his then workplace in Norwich, by defrauding a insurance companies of around £10,000 with fictitious claims for veterinary treatment on non-existent pets.
Following an investigation by the City of London Police's Insurance Fraud Enforcement Department (IFED), Mr da Cruz was convicted on five counts of fraud by false representation on 21 February 2013 at the Old Bailey in London, and later sentenced to eight months' imprisonment (suspended for two years) and 200 hours of unpaid community work; he was also ordered to pay just over £10,000 in compensation and costs.
Although Mr da Cruz had left the UK for Brazil shortly after his sentencing and was therefore not present at the hearing, the Committee was satisfied that he was deliberately evading the disciplinary proceedings, rather than being genuinely unable to participate in them, and so the hearing proceeded in his absence.
First accepting the copy certificate of conviction against Mr da Cruz as true, the Committee then had no hesitation in concluding that these convictions rendered him unfit to practise as a member of the veterinary profession. It found that the five counts of fraud were deliberate crimes of dishonesty, committed over a significant period of time and for significant financial gain. He had abused his position as a veterinary surgeon and abused the trust which the insurers placed in him as a professional.
Chairing and speaking on behalf of the Committee, Professor Peter Lees, said: "The Committee has no real confidence that there is no significant risk of repeat behaviour from the Respondent. His conduct subsequent to the criminal proceedings gives it no confidence that he has reformed himself to the extent that he will in the foreseeable future be fit to return to practice. So far from satisfactorily completing his criminal sentence, it appears that the Respondent has deliberately gone abroad to avoid doing so."
Bearing in mind that the purpose of any sanction it imposed was not to punish Mr da Cruz, but to maintain public confidence in the profession and uphold proper standards of conduct within it, the Committee concluded that the convictions were too serious to allow any sanction other than removal from the Register.
The full details of the Committee's decisions are available on the RCVS website (www.rcvs.org.uk/disciplinary).
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Northwest Surgeons, the Cheshire-based referral centre which is now part of Pets at Home, has announced the expansion of its clinical specialisms into the field of neurology, with the appointment of Dr Lorenzo Golini.
Dr Golini underwent residency training in neurology and neurosurgery at the University of Zurich where he remained as a clinician after his residency. He holds the European Diploma in Veterinary Neurology and a Master's degree in behavioural medicine. His main interests lie in epilepsy and MRI.
Dr Chris May, Northwest Surgeons' Managing Director said: "Neurology is a natural extension of the services we offer currently and is an area of growth in response to an increased demand from our referring vets. I am delighted to welcome Lorenzo to our team."
Dr Golini will accept referrals for both medical and surgical neurology cases, expanding on the case load seen by Northwest Surgeons' existing specialist teams which offer referrals in orthopaedic, soft tissue and spinal surgery and internal medicine. These services are supported by veterinary specialists in anaesthesia, pain management and diagnostic imaging.
For more information, visit: www.nwsurgeons.co.uk
MMI seeks to address mental health and wellbeing issues within the veterinary profession, while the Doctors’ Support Network provides peer support for doctors and medical students with mental health concerns.
&me was launched this time last year at the Palace of Westminster at an event sponsored by Kevan Jones MP (Labour, North Durham,) who has spoken about his own experiences with depression.
Overall eleven &me ambassadors have volunteered their own stories with mental ill-health:
A number of &me ambassadors will be taking part in an ‘&me live’ session at BSAVA Congress, from 5-8 April 2018 in Birmingham, providing a short overview of their story before taking questions from the audience. The session will take place from 8.30 to 10.10am on Saturday 7 April and will be open to all those attending Congress.
Lizzie Lockett, RCVS CEO and Mind Matters Director, said: "The feedback our &me ambassadors have received is truly heartening.
"Steve Carter, for example, had both an ex-student and colleague comment on his story thanking him for all he’s done, while a Facebook post about Rob Pettitt reached nearly 25,000 people.
"The campaign highlights how it is possible to recover from mental ill-health and flourish in your career, with the aim of encouraging those at the start of their mental ill-health experience to seek appropriate help, whether that is something profession-specific, such as Vetlife or DSN, or their GP."
Louise Freeman, Co-Chair of the DSN, added: "Many healthcare professionals face similar pressures that can lead to mental ill-health, including long hours, intense pressure, and the nature of the job which requires practitioners to constantly provide care for others, without necessarily recognising the need for self-care at the same time.
"A recurring theme that we’ve seen from these ambassadors’ stories has been that they drew on support from friends and family, and we really hope that this campaign encourages other professionals to seek help if they feel they are struggling."
The campaign is interested in hearing from not only doctors and veterinary surgeons but also nurses, veterinary nurses, dentists, pharmacists and other healthcare professionals who want to open up about their experiences of mental ill-health.
To participate in the campaign, email Dr Louise Freeman on vicechair@dsn.org.uk.
Further information about the ‘&me’ campaign can be found at www.vetmindmatters.org/&me, and a blog by Louise, 'Me and #AndMe', can be found at www.vetmindmatters.org/me-and-andme/.
The study, which was carried out by the VetCompass programme at the RVC, in partnership with Vets Now, also found that cats are most likely to be involved in a traffic accident in the autumn.
1,407 cat road traffic accident cases that attended Vets Now clinics across the UK between December 2011 and February 2014 were analysed, with researchers finding:
Younger cats, aged six months to six years, are at the greatest risk of road traffic accidents.
Male cats are 1.3 times more at risk of road traffic accidents than female cats.
Crossbred cats are 1.9 times more at risk of road traffic accidents compared to purebred cats.
Cats are more likely to be involved in a road traffic accident in the autumn. However, they are less at risk in winter as compared to spring.
Those cats that present with abdominal or spinal injuries are more likely to die, as are those that present with an increasing count of injuries.
RVC veterinary epidemiologist and VetCompass researcher Dr Dan O’Neill said: "One of the scariest times for any cat-owner is when they first start to let their cat go outside unattended. Owners of younger, and especially male, cats need to be especially vigilant. These results help owners to understand the true risks and therefore assist these owners to make the best decisions about if and how they let their cats go outside."
Dr Amanda Boag, Clinical Director of Vets Now, said: "We are very proud to have worked with VetCompass to ensure this important information about risks to our pet cats is made available to vets and the public. Working with our partners such as the RVC, we are committed to ensuring our large clinical database is used to help advance veterinary knowledge and understanding of emergency and critical care practice."
The full paper entitled 'Epidemiology of Road Traffic Accidents in Cats attending emergency-care practices in the UK' is published in the Journal of Small Animal Practice.
Dechra says the ability to split Prednicortone into 1.25 mg doses is particularly useful when used alongside Zycortal, the only licensed treatment for canine Addison’s disease in Europe.
Dechra Brand Manager Carol Morgan said: "Dogs with primary Addison’s disease have insufficient levels of natural mineralocorticoids (primarily aldosterone) and glucocorticoids (primarily cortisol). Zycortal contains DOCP, a synthetically produced steroid hormone, which acts in a similar way to aldosterone.
"It causes sodium retention and potassium excretion, helping to maintain water balance but Zycortal only replaces the mineralocorticoid. Therefore, a daily oral glucocorticoid treatment, such as Prednicortone, is needed to address the cortisol deficiency, alongside Zycortal.
"The amount of glucocorticoid administered should be adjusted to the individual dog’s need and it is likely that the dose required will be reduced over time."
She added that a combined approach of Zycortal and Prednicortone allowed independent dose titration of both mineralocorticoids and glucocorticoids.
"The advantage of prescribing the two treatments is that the dosage for each component can be tailored to an individual animal’s response. This leads to a reduction in the side effects usually associated with over-supplementation of glucocorticoids."
There are 250 tablets in a pack and Prednicortone offers accurate dosing using a double divisible SmartTab format and accurate dispensing via blister packs. The flavoured tablets also encourage easy oral administration.
For more information, visit www.dechra.co.uk.
The new products are:
Leon Wright, Managing Director, said: "At Vet Direct, we’re always looking for ways to improve our service – making small changes which will have a big impact on the levels of care our clients can provide.
"We know that vets, veterinary nurses and practice managers don’t always have the time to try out new products before purchasing, and that’s why our dedicated team of sales staff test every item before adding them to our catalogue - ensuring that we only stock the highest quality products."
For more information on any of the new products, visit www.vet-direct.com or call 0800 068 3300.
The company says that the packs have been redesigned to make it easier for pet owners to identify the variety of products available.
The new packaging has stronger imagery, simplified and larger product names to improve readability, and kibble shapes displayed actual size to reassure owners of smaller breeds that it will be suitable for their pet. Flavour profiles and breed sizes are displayed on all packs.
Hill's says the new range is also presented in optimised bag sizes for more convenient feeding. Small and Miniature and Mini dog foods have been combined into a new Small & Mini product, designed to cover the needs of all small dogs under 10kg.
For more information, visit: https://www.hillspet.co.uk/science-plan/new-look.
Some 150 practices currently use Vidivet, which was set up by Ben Sweeney MRCVS (pictured) in 2020.
He said: “I started VidiVet as I wanted people to be able to access high quality, impartial care for their pets that allows them to make more informed decisions around their treatment with expert information, rather than resorting to the internet.
"As a vet I also wanted to make life easier for those working within veterinary practices.
"VidiVet relieves part of the burden veterinary practices face by offering a trusted digital triage service for their clients.
"Our digital service can provide a helpful extension to a practice which dramatically reduces admin and saves time for the in-house team.
"Crucially, we offer peace of mind and reduce anxiety for pet owners, and with over 96% of VidiVet out of hours calls redirected to the pet owner’s registered vet, it can really enhance the practice bond by using digital care to augment physical care."
Before the Provet partnership, OOH case notes were sent to client practices which then had to enter them onto their systems manually.
Vidivet says the intregration with Provet means less admin and time savings for practices and a quicker follow up for pet owners.
https://vidivet.com
https://www.provet.cloud
A survey carried out by Rachel Crowe BSc PhD in association with Virbac Animal Health and VetSurgeon.org has revealed what veterinary surgeons in the UK expect from pharmaceutical companies and other suppliers.
The survey considers a number of different aspects of the relationship between vets and pharmaceutical companies, from the importance of quality products through to the question of what vets expect from company representatives.
Chris Liggett, Marketing Director at Virbac UK said: "The findings of this survey offer a fascinating insight into the relationship between veterinary practices and their suppliers. In some ways they confirm what we should all already know - that the quality of a company's product range is paramount and that representatives play a key role as ambassadors for our businesses - but the growing importance to vet practices of working with drug companies that provide a complete package of products and services is worthy of note."
The full report is available to download here.